These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30594572)

  • 41. Percutaneous closure of patent foramen ovale in cryptogenic embolism.
    Meier B; Kalesan B; Mattle HP; Khattab AA; Hildick-Smith D; Dudek D; Andersen G; Ibrahim R; Schuler G; Walton AS; Wahl A; Windecker S; Jüni P;
    N Engl J Med; 2013 Mar; 368(12):1083-91. PubMed ID: 23514285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Closure versus Medical Therapy for Patent Foramen Ovale in Patients with Cryptogenic Stroke: An Updated Meta-Analysis of Randomized Controlled Trials.
    Qiu B; Cai Y; Wang D; Lin J; Fan Y
    J Stroke Cerebrovasc Dis; 2018 Dec; 27(12):3463-3472. PubMed ID: 30185398
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of different devices for transcatheter closure of patent foramen ovale assessed by serial transoesophageal echocardiography and rates of recurrent cerebrovascular events in a long-term follow-up.
    Luani B; Markovic S; Krumsdorf U; Rottbauer W; Wöhrle J
    EuroIntervention; 2015 May; 11(1):85-91. PubMed ID: 25572024
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Percutaneous closure of patent foramen ovale: safe and effective but underutilized.
    Nietlispach F; Meier B
    Expert Rev Cardiovasc Ther; 2015 Feb; 13(2):121-3. PubMed ID: 25556896
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recurrent stroke and patent foramen ovale: a systematic review and meta-analysis.
    Katsanos AH; Spence JD; Bogiatzi C; Parissis J; Giannopoulos S; Frogoudaki A; Safouris A; Voumvourakis K; Tsivgoulis G
    Stroke; 2014 Nov; 45(11):3352-9. PubMed ID: 25293664
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cryptogenic Stroke and Patent Foramen Ovale Risk Assessment.
    Melkumova E; Thaler DE
    Interv Cardiol Clin; 2017 Oct; 6(4):487-493. PubMed ID: 28886840
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis.
    Stortecky S; da Costa BR; Mattle HP; Carroll J; Hornung M; Sievert H; Trelle S; Windecker S; Meier B; Jüni P
    Eur Heart J; 2015 Jan; 36(2):120-8. PubMed ID: 25112661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Initial experience with the novel patent foramen ovale occlusion device Nit-Occlud® in patients with stroke or transient ischemic attack.
    Steinberg DH; Bertog SC; Momberger J; Franke J; Hofmann I; Renkhoff K; Joy S; Vaskelyte L; Sievert H
    Catheter Cardiovasc Interv; 2015 Jun; 85(7):1262-7. PubMed ID: 24948394
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Second device for a patent foramen ovale: life saver and psychotherapy.
    Meier B
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):151-2. PubMed ID: 20578221
    [No Abstract]   [Full Text] [Related]  

  • 50. Patent foramen ovale.
    Dattilo PB; Kim MS; Carroll JD
    Cardiol Clin; 2013 Aug; 31(3):401-15. PubMed ID: 23931102
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.
    Carroll JD; Saver JL; Thaler DE; Smalling RW; Berry S; MacDonald LA; Marks DS; Tirschwell DL;
    N Engl J Med; 2013 Mar; 368(12):1092-100. PubMed ID: 23514286
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Transcatheter closure of patent foramen ovale following cryptogenic stroke: An updated meta-analysis of randomized controlled trials.
    Riaz H; Khan MS; Schenone AL; Waheed AA; Khan AR; Krasuski RA
    Am Heart J; 2018 May; 199():44-50. PubMed ID: 29754665
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patent foramen ovale and cryptogenic stroke: the hole story.
    Furlan AJ; Jauss M
    Stroke; 2013 Sep; 44(9):2676-8. PubMed ID: 23908069
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Secondary prevention of ischaemic stroke.
    Muller C; Roizman M; Wong A
    Intern Med J; 2019 Oct; 49(10):1221-1228. PubMed ID: 31602772
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multidisciplinary Assessment in Optimising Results of Percutaneous Patent Foramen Ovale Closure.
    Davies A; Ekmejian A; Collins N; Bhagwandeen R
    Heart Lung Circ; 2017 Mar; 26(3):246-250. PubMed ID: 27555053
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patent Foramen Ovale: A Comprehensive Review.
    Teshome MK; Najib K; Nwagbara CC; Akinseye OA; Ibebuogu UN
    Curr Probl Cardiol; 2020 Feb; 45(2):100392. PubMed ID: 30327131
    [No Abstract]   [Full Text] [Related]  

  • 57. Successful percutaneous transcatheter patent foramen ovale closure through the right internal jugular vein using a steerable catheter.
    Hascoet S; Fraisse A; Elbaz M
    Catheter Cardiovasc Interv; 2013 Oct; 82(4):E598-602. PubMed ID: 23413211
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potentially large yet uncertain benefits: a meta-analysis of patent foramen ovale closure trials.
    Kitsios GD; Thaler DE; Kent DM
    Stroke; 2013 Sep; 44(9):2640-3. PubMed ID: 23868270
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predictors of recurrent stroke after percutaneous closure of patent foramen ovale.
    Rudolph V; Augustin J; Hofmann T; Hamm CW; Meinertz T; Köster R; Baldus S; Franzen O
    EuroIntervention; 2014; 9(12):1418-22. PubMed ID: 24169021
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patent foramen ovale closure to prevent secondary neurologic events.
    Jasper R; Blankenship JC
    Eur J Intern Med; 2017 Oct; 44():1-11. PubMed ID: 28684051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.